# Valneva SE: financial statements, quarterly

VALN · Nasdaq · CIK 1836564 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/valn.md) · [Financials](/companies/valn/financials.md) · [Filings](/companies/valn/filings.md) · [Insiders](/companies/valn/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/valn/financials.md?period=annual).

## Balance sheet

| Line item | Unit | period not labelled (2018-12-31) | period not labelled (2019-12-31) | period not labelled (2020-12-31) | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | not reported | [64.4](/filings/0001387131-22-003914.md) | [204](/filings/0001628280-23-009890.md) | [347](/filings/0001628280-23-009890.md) | [287](/filings/0001628280-26-018808.md) | [126](/filings/0001628280-26-018808.md) | [168](/filings/0001628280-26-018808.md) | [110](/filings/0001628280-26-018808.md) |
| Current assets | $m | not reported | not reported | [308](/filings/0001387131-22-003914.md) | [586](/filings/0001628280-23-009890.md) | [425](/filings/0001628280-24-012747.md) | [263](/filings/0001628280-25-014522.md) | [299](/filings/0001628280-26-018808.md) | [223](/filings/0001628280-26-018808.md) |
| Total assets | $m | not reported | not reported | [449](/filings/0001387131-22-003914.md) | [817](/filings/0001628280-23-009890.md) | [621](/filings/0001628280-24-012747.md) | [460](/filings/0001628280-25-014522.md) | [500](/filings/0001628280-26-018808.md) | [399](/filings/0001628280-26-018808.md) |
| Current liabilities | $m | not reported | not reported | [176](/filings/0001387131-22-003914.md) | [369](/filings/0001628280-23-009890.md) | [277](/filings/0001628280-24-012747.md) | [159](/filings/0001628280-25-014522.md) | [115](/filings/0001628280-26-018808.md) | [93.3](/filings/0001628280-26-018808.md) |
| Total liabilities | $m | not reported | not reported | [372](/filings/0001387131-22-003914.md) | [647](/filings/0001628280-23-009890.md) | [402](/filings/0001628280-24-012747.md) | [332](/filings/0001628280-25-014522.md) | [319](/filings/0001628280-26-018808.md) | [293](/filings/0001628280-26-018808.md) |
| Shareholders' equity | $m | [134](/filings/0001387131-22-003914.md) | [135](/filings/0001628280-23-009890.md) | [77.4](/filings/0001628280-24-012747.md) | [171](/filings/0001628280-25-014522.md) | [220](/filings/0001628280-26-018808.md) | [128](/filings/0001628280-26-018808.md) | [181](/filings/0001628280-26-018808.md) | [106](/filings/0001628280-26-018808.md) |

- Cash and equivalents: ifrs-full:CashAndCashEquivalents
- Current assets: ifrs-full:CurrentAssets
- Total assets: ifrs-full:Assets
- Current liabilities: ifrs-full:CurrentLiabilities
- Total liabilities: ifrs-full:Liabilities
- Shareholders' equity: ifrs-full:Equity

Shares outstanding: 173,539,745 at 2025-12-31, from the cover of the [20-F filed 2026-03-17](/filings/0001628280-26-018808.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:49 ET. No prices; not investment advice.